肿瘤细胞治疗研究
英文原题：Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances.
嵌合抗原受体（CAR）-T细胞疗法是近年来肿瘤血液学领域最重要的创新。
嵌合抗原受体（CAR）-T细胞疗法是近年来肿瘤血液学领域最重要的创新。并发症管理方面取得的进展以及最新一代CAR-T细胞使得在二线治疗中提前应用该类型治疗大B细胞淋巴瘤的适应证成为可能。虽然某些类型的B细胞淋巴瘤和B细胞急性淋巴细胞白血病已显示出极其有希望的结果，但髓系白血病——特别是急性髓系白血病（AML）——的情况并非如此，而AML比其他任何血液疾病都更需要创新疗法。AML细胞的异质性以及骨髓微环境与白血病细胞之间相互作用的免疫复杂性已被发现是CAR-T在AML中临床开发的主要障碍。在这篇综述中，我们报告了AML临床试验中取得的主要结果、测试潜在CAR-T构建体的临床前研究以及未来展望。
Chimeric antigen receptors (CAR)-T-cell therapy represents the most important innovation in onco-hematology in recent years. The progress achieved in the management of complications and the latest generations of CAR-T-cells have made it possible to anticipate in second-line the indication of this type of treatment in large B-cell lymphoma. While some types of B-cell lymphomas and B-cell acute lymphoid leukemia have shown extremely promising results, the same cannot be said for myeloid leukemias-in particular, acute myeloid leukemia (AML), which would require innovative therapies more than any other blood disease. The heterogeneities of AML cells and the immunological complexity of the interactions between the bone marrow microenvironment and leukemia cells have been found to be major obstacles to the clinical development of CAR-T in AML. In this review, we report on the main results obtained in AML clinical trials, the preclinical studies testing potential CAR-T constructs, and future perspectives.
MEMBER ACCOUNT
登录成功会直接打开下一页。
